Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income towards Parent Company (2020 - 2025)

Silence Therapeutics' Income towards Parent Company history spans 6 years, with the latest figure at $77.9 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 533.3% to $77.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 102.08% increase, with the full-year FY2025 number at $1.1 million, up 102.35% from a year prior.
  • Income towards Parent Company hit $77.9 million in Q4 2025 for Silence Therapeutics, up from -$21.0 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for SLN hit a ceiling of $77.9 million in Q4 2025 and a floor of -$39.2 million in Q3 2024.
  • Historically, Income towards Parent Company has averaged -$11.7 million across 5 years, with a median of -$16.0 million in 2021.
  • The widest YoY moves for Income towards Parent Company: up 533.3% in 2025, down 1134.0% in 2025.
  • Tracing SLN's Income towards Parent Company over 5 years: stood at -$15.1 million in 2021, then decreased by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then soared by 166.23% to $12.3 million in 2024, then skyrocketed by 533.3% to $77.9 million in 2025.
  • Business Quant data shows Income towards Parent Company for SLN at $77.9 million in Q4 2025, -$21.0 million in Q3 2025, and -$27.4 million in Q2 2025.